Dafinchi AI

EMBC

Healthcare

Adjusted EBITDA was $131 million with a margin of 44.3%, up from 36.4% prior year.
Adjusted operating income was $109.1 million with a margin of 36.9%, up from 30.6% prior year, driven by lower R&D expenses and higher revenue.
Debt reduction of $52 million in Q3, totaling $112 million year-to-date, exceeding the fiscal 2025 target.
Embecta reported Q3 2025 revenue of $295.5 million, an 8.4% increase on an as-reported basis and 8% on an adjusted constant currency basis.
Free cash flow was approximately $81 million in Q3, including $26 million from trade receivables factoring.
GAAP gross profit was $197.1 million with a margin of 66.7%, down from 69.8% prior year due to less favorable profit and inventory adjustments.
GAAP net income was $45.5 million ($0.78 per diluted share), adjusted net income was $65.5 million ($1.12 per diluted share), both significantly higher than prior year.
International revenue grew 5.0% reported and 4.2% adjusted constant currency, with growth in Latin America and Asia offset by a decline in China.
Pen needle revenue increased 6.8%, syringe revenue grew 14.5%, safety products grew 6.5%, and contract manufacturing surged 47.2%.
U.S. revenue grew 11.6% year-over-year on an adjusted constant currency basis, driven by pricing and volume increases.

MRK

Healthcare

Animal Health sales grew 11%, driven by livestock demand and aqua portfolio acquisition.
CAPVAXIVE sales were $129 million, driven by demand from retail and non-retail customers.
Earnings per share were $2.13 on a non-GAAP basis.
Excluding China, global growth was 7%, driven by oncology, Animal Health, and new products WINREVAIR and CAPVAXIVE.
GARDASIL sales declined by approximately $1.3 billion in China, reducing growth by 9 percentage points.
GARDASIL sales were $1.1 billion, down 55% primarily due to China; excluding China, sales declined 4%.
Gross margin was 82.2%, up 1.3 percentage points due to favorable product mix.
KEYTRUDA sales increased 9% to $8 billion, with growth in metastatic and earlier-stage cancers.
Merck reported Q2 2025 revenue of $15.8 billion, a 2% decrease nominally and excluding foreign exchange impact.
Operating expenses increased to $6.6 billion, including a $200 million charge related to a license agreement.
VAXNEUVANCE sales increased 20%, with U.S. growth partly due to CDC stockpile activity.
WELIREG sales increased 29% to $162 million, driven by use in advanced renal cell carcinoma.
WINREVAIR sales reached $336 million globally, with cumulative net sales exceeding $1 billion in 15 months.

Earnings Feed